Korro Bio (KRRO) vs Jyong Biotech (MENS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Korro Bio (KRRO) has outperformed Jyong Biotech (MENS) over the past year, losing 78.3% versus a loss of 96.1%. Jyong Biotech is the larger company by market cap ($159.7 million vs $149.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | KRRO | MENS |
|---|---|---|
| Share price | $10.16 | $2.10 |
| Market cap | $149.61M | $159.66M |
| 1-day change | -3.97% | 0.00% |
| YTD return | +26.84% | -46.84% |
| 1-year return | -78.26% | -96.12% |
| 5-year return | -97.14% | — |
| EPS (TTM) | $-9.88 | $-0.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $55.89 | $63.00 |
| 52-week low | $5.20 | $1.43 |
| Distance from 52-week high | -81.82% | -96.67% |
| Analyst consensus | strong_buy | — |
| Avg. price target upside | +98.82% | — |
| Average volume | 147.29K | 45.47K |
| Shares outstanding | 14.73M | 74.23M |
| Employees | 57 | 27 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KRRO has outperformed MENS by 17.9 percentage points over the past year.
About Korro Bio
KRRO stock →Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company's lead product candidate is KRRO-121 for the treatment for hyperammonemia.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About Jyong Biotech
MENS stock →Jyong Biotech Ltd., a science-driven biotechnology company, engages in the development and commercialization of plant-derived drugs for the treatment of urinary system diseases in the United States, the European Union, and Asia. It develops Botreso, for the treatment of benign prostate hyperplasia/lower urinary tract symptoms; PCP for treating prostate cancer; and interstitial cystitis (IC) for the treatment of IC/bladder pain syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 27 employees
KRRO vs MENS FAQ
Which is bigger, Korro Bio or Jyong Biotech?
Jyong Biotech (MENS) is larger, with a market capitalization of $159.66M compared with $149.61M for Korro Bio (KRRO).
Which stock has performed better over the past year, KRRO or MENS?
KRRO returned -78.26% over the past 12 months, compared with -96.12% for MENS (price return, excluding dividends). Past performance does not predict future results.
Are Korro Bio and Jyong Biotech in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.